Yahoo
NasdaqGM - Delayed Quote USD

Oruka Therapeutics, Inc. (ORKA)

92.51 +1.52 (+1.67%)
At close: September 4 at 4:00:00 PM EDT
92.51 0.00 (0.00%)
After hours: September 4 at 7:30:02 PM EDT
Trade ORKA on Coinbase
Chart Range Bar
Loading chart for ORKA
  • Previous Close 90.99
  • Open 90.06
  • Bid 71.53 x 200
  • Ask 126.45 x 200
  • Day's Range 89.75 - 93.98
  • 52 Week Range 14.67 - 115.52
  • Volume 600,469
  • Avg. Volume 1,177,331
  • Market Cap (intraday) 6.125B
  • Beta (5Y Monthly) -0.21
  • PE Ratio (TTM) --
  • EPS (TTM) -2.04
  • Earnings Date (est.) Nov 11, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 155.00

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

orukatx.com

68

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ORKA
205.21%
S&P 500 (^GSPC)
12.75%

1-Year Return

ORKA
517.97%
S&P 500 (^GSPC)
18.71%

3-Year Return

ORKA
595.83%
S&P 500 (^GSPC)
70.93%

5-Year Return

ORKA
362.39%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -31.82M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

-30M
-20M
-10M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

117.00
155.00 Average
92.51 Current
200.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/3/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 120 -> 120

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    6.10B

  • Enterprise Value

    5.23B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    5.49

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -12.95%

  • Return on Equity (ttm)

    -18.23%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -109.69M

  • Diluted EPS (ttm)

    -2.04

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    873.56M

  • Total Debt/Equity (mrq)

    0.23%

  • Levered Free Cash Flow (ttm)

    -65.03M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

92.51 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: